Metronomic chemotherapy (mCHT) in HER2-ve advanced breast cancer (ABC) patients (pts): What has changed over the time? Preliminary results of the VICTOR-6 study.Marina Elena Cazzaniga, Rosalba Rossello, Salvatore Russo et al.|Journal of Clinical Oncology|2017Cited by 2
Metronomic Chemotherapy (mCHT) in HER2-ve Advanced Breast Cancer (ABC) Patients (PTS): When Care Objectives Meet Patients’ Need. Preliminary Results of the Victor-6 StudyMarina Elena Cazzaniga, Valter Torri, Maria Rosaria Valerio et al.|The Breast|2017Cited by 0
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Change of Molecular Subtype at Re-Biopsy. Insights from the GIM-13 - AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Preprints.org|2025Cited by 0
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA StudyMarina Elena Cazzaniga, Giorgio Mustacchi, P. Pronzato et al.|Cancers|2025Cited by 0
Abstract GS3-02: Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) studyM. Lambertini, Lucia Del Mastro, Eva Blondeaux et al.|Clinical Cancer Research|2026Cited by 0